Genprex Q1 Cash $18.05M, Net Loss $(4.46M); Extends Runway to H2 2027
Genprex, Inc. reported a net loss of $(4.46) million for the first quarter of 2026, an increase from $(3.96) million in the prior year, though net loss per share improved significantly to $(0.64) due to a higher share count. The company's cash and cash equivalents substantially increased to $18.05 million as of March 31, 2026, driven by $13.36 million in net proceeds from common stock issuances. This financing is expected to fund operations and clinical trials into the second half of 2027, despite ongoing operating losses and a going concern warning. Genprex also provided updates on its Acclaim-1 and Acclaim-3 clinical trials, with interim analyses anticipated in the second half of 2026, and noted the formation of Convergen Biotech, Inc. for a potential diabetes program separation.
Key Highlights
- Cash and cash equivalents rose to $18.05 million as of March 31, 2026, from $7.83 million at December 31, 2025.
- Net loss for Q1 2026 was $(4.46) million, compared to $(3.96) million for Q1 2025.
- Net loss per share improved to $(0.64) for Q1 2026 from $(12.98) for Q1 2025, due to increased shares.
- Net cash provided by financing activities was $13.36 million in Q1 2026, primarily from common stock issuances.
- Company expects current cash to fund operations and clinical trials into the second half of 2027.
- Acclaim-1 (NSCLC) and Acclaim-3 (SCLC) Phase 2a/2 expansion portions are enrolling patients, with interim analyses expected in H2 2026.
- Genprex formed a wholly-owned subsidiary, Convergen Biotech, Inc., in February 2025 for potential diabetes program separation.